Social Security Minister Elaine Millar approved changes to Jersey’s Prescribed List with effect from 1 September 2026, following recommendations from the Pharmaceutical Benefit Advisory Committee. The Jersey Evening Post reported the changes carry a combined annual cost of £105,000 to the Health Insurance Fund. New additions include: fezolinetant (moderate to severe menopausal vasomotor symptoms); isotretinoin (severe acne); relugolix (hormone-sensitive prostate cancer); and a medicine for erectile dysfunction. Fezolinetant is notable as it was accepted by the SMC for NHS Scotland in July 2026 within a Patient Access Scheme, suggesting the undiscounted price was not considered cost-effective without a discount — Jersey’s adoption at full list price represents a different commissioning approach. 1
Blueteq comment: Jersey’s adoption of fezolinetant ahead of any formal NICE technology appraisal for England illustrates the island’s practice of making additions to the Prescribed List based on PBAC recommendations, rather than following the NICE or SMC pathways.
References
1. Latest medicines added to prescription list at £105,000 annual cost. Jersey Evening Post. 24 August 2026. https://jerseyeveningpost.com/news/2026/08/24/latest-medicines-added-to-prescription-list-at-105000-annual-cost/
